“No matter how good an inhaled drug is, it cannot be effective if people are unable to use their inhalers to get it into the lungs”
“Why can't someone make a device that takes the problems and worry
out of using my inhalers?”
Inhaler misuse is common among both patients and healthcare providers. The results? Wasted medication, increased medication side effects, and poorer asthma and COPD control No one should have to wonder if their inhalers are going to work for them each and every time.
The InspirEaseHFA Solution
90% OF PATIENTS FAIL TO OBTAIN THE INTENDED BENEFITS FROM INHALED MEDICATIONS DUE TO INHALER MISUSE
85% OF HEALTHCARE PROVIDERS ARE UNABLE TO DEMONSTRATE OR INSTRUCT PROPER INHALER TECHNIQUE
OVER $7 BILLION DOLLARS ANNUALLY IS ATTRIBUTED TO INHALER MISUSE
The patient experience is at the core of all that we do at Abithas, Inc.. Our main goal is to use keep it simple technology solutions to address the problems and concerns that people have using common metered-dose inhalers ("MDIs") and rigid, tube type spacer devices.
Up to 87% of MDI users fail to use current rigid, tube type spacers regularly. Ask yourself, why wouldn't someone use a device if they clearly benefit from it?.
That's why we developed the investigationa InspirEase®HFA device.
Using an MDI with the InspirEase®HFA (iHFA®), inhaler users have confidence, knowing that every puff of medication gets into their lungs, each and every time. The iHFA® helps to prevent and eliminate patient characteristics that result in MDI misuse.
Get in touch with us to learn more about the InspirEase®HFA.
Simply attach a press and breathe MDI to the InspirEase®HFA,
open the device, trigger the inhaler, and breathe in.
As you breathe in, the bag collapses without making a sound
As you breathe in, the bag collapses, and a whistle sounds if you inhaled too fast
Edward Lisberg, MD FCCP CPI
Abithas, Inc. is leading innovation in patient-centered, inhaler spacer technology. Founded by Edward Lisberg, MD FCCP CPI, a respiratory specialist with decades of experience as a Principal Investigator (over 160 phase 2 and 3 clinical trials), and as an experienced clinician in asthma and COPD.
"The lives of too many people with asthma and COPD are needlessly impaired due to
inhaler misuse. Too few companies and healthcare providers seem to take notice or
care that patients need a better solution. The InspirEaseHFA is that solution"
The InspirEaseHFA is recipient of 2021 two international awards that recognize significant achievements in medical product design and engineering that improve the quality of healthcare delivery and accessibility.
"The first innovation in its class in decades"
Are you an Angel Investor? Abithas, Inc. is certified as a Qualified New Business Venture (QNBV) under the Illinois Angel Investment Tax Credit Program (#116J). Investors in companies that are certified as QNBVs can receive a state tax credit equal to 25% of their investment (up to $2 million).Accredited investors seeking information use the form below to contact us.